Orfagen: Clinical Trials

4 completed. 2 Phase 2, 2 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	2	Completed 2
Phase 3	2	Completed 2

Follow Orfagen: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU) Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209), Ti02 pigmentary 3% alone (formula RV3131A-MV1211), bisoctrizole 10% alone (formula RV3131A-MV1237) - Idiopathic Solar Urticaria	Phase 2	Completed	Orfagen	16	2007-09-01	2017-12-22
Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study. Ethanol 96% Gel, Ethanol 98% Solution - Congenital Venous Malformation	Phase 2	Completed	Orfagen	32	2007-05-01	2015-01-15
Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis V0034CR01B, V0034CR01B vehicle - Uremic Xerosis	Phase 3	Completed	Orfagen	237	2007-01-01	2017-12-20
Efficacy, Local Tolerance and Patient Acceptability of a Moisturizing Emollient in Patients With Uremic Xerosis V0034 CR - Uremic Xerosis	Phase 3	Completed	Orfagen	100	2002-12-01	2010-03-10

Interventions

Ethanol (1)  ·  Gels (1)  ·  Single Person (1)  ·  Solutions (1)  ·  titanium dioxide (1)

Countries

United States (2)  ·  France (1)  ·  United Kingdom (1)

Top investigators

Jacek Szepietowski, Professor (1)  ·  James Ferguson, Pr (1)  ·  Patrick Dupuy, Dr (1)

Results publications

PMID 39422853